Vanguard Medica to acquire Cerebrus
After a week of speculation, Vanguard Medica has confirmed that itintends to acquire the troubled UK biotechnology company Cerebrus in a stock deal valued at L9.6 million ($15.4 million). The new group is expected to be renamed Vernalis.
Cerebrus specializes in discovering and developing therapeutics for disorders of the central nervous system, and Vanguard says that it will be undertaking a detailed operating review, looking at the scientific, commercial and financial information "to maximize the opportunities arising from merging the two businesses."
Robert Mansfield, chief executive of Vanguard, said that the combination of the two firms creates a new company "with exciting potential and a complementary skills base." Furthermore, the unveiling of a Cerebrus/Roche collaboration deal on obesity (at the same time as the merger announcement) "provides a strong validation of the quality of the science at Cerebrus and the calibre of its research team."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze